MarketCap
Facebook
X
Telegram
Country |
 USA |
IPO year |
2020 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
61.4 M |
Market Cap[1] |
$ 47.9 M |
EBITDA (LTM) |
$ -155 M |
P/E (LTM) |
-0.477366 |
P/S (LTM) |
- |
EPS (LTM) |
-2.43 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
C4 Therapeutics
CCCC
|
$ 3.0 | -4.76 % | $ 249 M | Nasdaq Global Select Market | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 1.67 | -0.6 % | $ 2.75 M | NYSE American |  Israel |
 |
Cytokinetics, Incorporated
CYTK
|
$ 56.2 | 1.92 % | $ 6.75 M | Nasdaq Global Select Market,SPB | USA |
 |
Curis
CRIS
|
$ 0.66 | -5.68 % | $ 8.69 M | Nasdaq Global Market | USA |
 |
Exelixis
EXEL
|
$ 71.0 | -1.04 % | $ 19.3 B | Nasdaq Global Select Market,SPB | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Amgen
AMGN
|
$ 465.26 | 0.01 % | $ 250 B | Nasdaq Global Select Market,SPB | USA |
 |
Biogen
BIIB
|
$ 253.37 | -0.59 % | $ 37.1 B | Nasdaq Global Select Market,SPB | USA |
 |
Edesa Biotech
EDSA
|
$ 2.01 | -19.28 % | $ 11.4 M | Nasdaq Capital Market | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$ 15.12 | -0.72 % | $ 978 M | NYSE | USA |
 |
Achieve Life Sciences
ACHV
|
$ 6.78 | 0.89 % | $ 296 M | Nasdaq Capital Market | USA |
 |
Fulcrum Therapeutics
FULC
|
$ 3.72 | -0.13 % | $ 236 M | Nasdaq Global Market | USA |
 |
Immutep Limited
IMMP
|
$ 3.53 | -7.11 % | $ 5.14 B | Nasdaq Global Market |  Australia |
 |
Iovance Biotherapeutics
IOVA
|
$ 8.09 | -1.04 % | $ 2.89 M | Nasdaq Global Market,SPB | USA |
 |
Evogene Ltd.
EVGN
|
$ 0.37 | 28.7 % | $ 2.91 M | Nasdaq Global Market | Israel |
 |
Armata Pharmaceuticals
ARMP
|
$ 3.71 | -2.5 % | $ 134 M | NYSE American | USA |
 |
Axsome Therapeutics
AXSM
|
$ 141.12 | 5.34 % | $ 7.02 B | Nasdaq Global Market,SPB | USA |
 |
Keros Therapeutics
KROS
|
$ 9.32 | 1.64 % | $ 347 M | Nasdaq Global Select Market | USA |
 |
Champions Oncology
CSBR
|
$ 4.85 | 0.21 % | $ 67.1 M | Nasdaq Capital Market | USA |
 |
Fennec Pharmaceuticals
FENC
|
$ 10.6 | -2.12 % | $ 303 M | Nasdaq Capital Market | USA |
|
Forte Biosciences
FBRX
|
$ 76.99 | 0.03 % | $ 997 M | Nasdaq Capital Market | USA |
 |
Immunic
IMUX
|
$ 8.06 | 1.26 % | $ 1.25 B | Nasdaq Global Select Market | USA |
 |
DiaMedica Therapeutics
DMAC
|
$ 9.7 | 0.47 % | $ 456 M | Nasdaq Capital Market | USA |
 |
Grifols, S.A.
GRFS
|
$ 8.74 | 0.63 % | $ 5.94 B | Nasdaq Global Select Market |  Spain |
 |
Incyte Corporation
INCY
|
$ 120.28 | -1.32 % | $ 23.5 B | Nasdaq Global Select Market,SPB | USA |
 |
AC Immune SA
ACIU
|
$ 2.32 | -4.92 % | $ 234 M | Nasdaq Global Market |  Schweiz |
 |
Aldeyra Therapeutics
ALDX
|
$ 0.64 | 0.53 % | $ 38.4 M | Nasdaq Global Select Market | USA |
 |
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Nasdaq Capital Market |  Canada |
 |
Precision BioSciences
DTIL
|
$ 9.47 | -2.17 % | $ 121 M | Nasdaq Global Select Market | USA |
 |
AIM ImmunoTech
AIM
|
$ 0.14 | -11.15 % | $ 227 K | NYSE American | USA |
 |
Ascendis Pharma A/S
ASND
|
$ 256.21 | -1.4 % | $ 15.5 B | Nasdaq Global Select Market |  Danmark |
 |
ANI Pharmaceuticals
ANIP
|
$ 71.31 | 5.19 % | $ 1.43 B | Nasdaq Global Market,SPB | USA |
 |
Actinium Pharmaceuticals
ATNM
|
$ 1.56 | 1.3 % | $ 48.7 M | NYSE American | USA |
 |
Autolus Therapeutics plc
AUTL
|
$ 1.31 | -0.76 % | $ 349 M | Nasdaq Global Select Market |  Britain |
|
Monopar Therapeutics
MNPR
|
$ 71.42 | -3.16 % | $ 529 M | Nasdaq Global Select Market | USA |
 |
BridgeBio Pharma
BBIO
|
$ 78.67 | 0.95 % | $ 15.1 B | Nasdaq Global Select Market,SPB | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
$ 7.53 | -1.38 % | $ 1.58 B | Nasdaq Global Select Market | USA |
 |
Bicycle Therapeutics plc
BCYC
|
$ 3.68 | -2.39 % | $ 255 M | Nasdaq Global Select Market | Britain |
 |
Coherus BioSciences
CHRS
|
$ 0.64 | -21.66 % | $ 75 M | Nasdaq Global Market | USA |
 |
Arcutis Biotherapeutics
ARQT
|
$ 27.45 | 4.77 % | $ 3.49 B | Nasdaq Global Select Market,SPB | USA |
 |
Cellectis S.A.
CLLS
|
$ 1.12 | -0.45 % | $ 112 M | Nasdaq Global Market |  France |
 |
BeyondSpring
BYSI
|
$ 0.6 | -2.21 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Alkermes plc
ALKS
|
$ 46.48 | 0.67 % | $ 7.66 B | Nasdaq Global Select Market |  Irlanda |
 |
Altimmune
ALT
|
$ 1.94 | -8.51 % | $ 171 M | Nasdaq Global Market | USA |
 |
Cardiff Oncology
CRDF
|
$ 0.79 | -0.77 % | $ 52.8 M | Nasdaq Capital Market | USA |
 |
Citius Pharmaceuticals
CTXR
|
$ 0.5 | -5.43 % | $ 5.53 M | Nasdaq Capital Market | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
$ 9.41 | -0.84 % | $ 258 M | Nasdaq Global Market,SPB | Israel |
 |
Arrowhead Pharmaceuticals
ARWR
|
$ 49.04 | -0.41 % | $ 6.56 B | Nasdaq Global Select Market,SPB | USA |
 |
Atara Biotherapeutics
ATRA
|
$ 8.18 | -0.73 % | $ 103 M | Nasdaq Global Select Market,SPB | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
$ 16.3 | -1.93 % | $ 2.19 B | Nasdaq Global Market | Canada |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.